Cancer remains one of the most prevalent diseases to date. Detection of circulating tumor cells (CTCs) in the vasculature has been identified as a promising method for determination of cancer risk, cancer prognosis, and determination of the effect of therapy. This proposal aims to establish the feasibility of a system for optical detection of CTCs that could be used in a point-of-care setting. Nanoparticles doped with near-infrared fluorophores and with high affinity to the cancer cells will be utilized for tagging CTCs in blood samples. The nanoparticles will provide high signal amplification for ultrasensitive detection. Phase I will focus on the evaluation of the diagnostic setup using body fluids spiked with CTCs. Phase II will develop a prototype and optimize the system for detection of patient samples. This project is expected to result in a small and rapid sensor that could be used at a physician's office or at small diagnostic laboratories, and which could become essential for the diagnosis and management of cancer patients.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Small Business Innovation Research – Phase I (N43)
Project #
261201000050C-0-0-1
Application #
8179082
Study Section
Project Start
2010-09-30
Project End
2011-06-29
Budget Start
Budget End
Support Year
Fiscal Year
2010
Total Cost
$200,000
Indirect Cost
Name
Innosense, LLC
Department
Type
DUNS #
114060861
City
Torrance
State
CA
Country
United States
Zip Code
90505